| Name | 2-(1H-benzimidazol-2-ylsulfanyl)-N'-[(3-bromo-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]propanehydrazide |
|---|---|
| Synonyms |
Propanoic acid, 2-(1H-benzimidazol-2-ylthio)-, 2-[(1E)-(5-bromo-2-hydroxyphenyl)methylene]hydrazide
2-(1H-Benzimidazol-2-ylsulfanyl)-N'-[(E)-(5-bromo-2-hydroxyphenyl)methylene]propanehydrazide MNI-caged-L-glutamate KH7 (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N'-(5-bromo-2-hydroxybenzylidene)propanehydrazide |
| Description | KH7 is a soluble adenylyl cyclase (sAC)-specific inhibitor, with IC50s of 3-10 μM toward both recombinant purified human sACt protein and heterologously expressed sACt in cellular assays[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 3-10 μM (recombinant sACt)[1]. |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Molecular Formula | C17H15BrN4O2S |
| Molecular Weight | 419.296 |
| Exact Mass | 418.009888 |
| PSA | 115.67000 |
| LogP | 6.01 |
| Index of Refraction | 1.716 |
| Storage condition | 2-8℃ |
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301 |
| Precautionary Statements | P301 + P310 |
| RIDADR | UN 2811 6.1 / PGIII |